CORPORATE PRESENTATION€¦ · presentation and, except as required by applicable law, the Company...

CORPORATE PRESENTATIONJuly 24, 2020

www.evecannabis.ca | TSX-V: EVE | OTCQX: EEVVF

FORWARD LOOKING STATEMENT

2www.evecannabis.ca | TSX-V: EVE | OTCQX: EEVVF

IMPORTANT: YOU MUST READ THE FOLLOWING The information contained in this presentation has been prepared by Eve & CoIncorporated (“Eve & Co” or the “Company”) and contains confidentialinformation pertaining to the business, operations and assets of the Company.The information contained in this presentation (a) is provided as at the datehereof and is subject to change without notice, (b) does not purport to containall the information that may be necessary or desirable to fully and accuratelyevaluate an investment in the Company, and (c) is not to be considered as arecommendation by the Company that any person make an investment in EVE.An investment in the securities described herein is speculative and involves anumber of risks that should be considered by a prospective investor.

This presentation is confidential and is being provided to you solely for yourinformation and may not be reproduced, in whole or in part, in any form orforwarded or further distributed to any other person. Any forwarding,distribution or reproduction of this presentation in whole or in part isunauthorized. By accepting and reviewing this presentation, you acknowledgeand agree (i) to maintain the confidentiality of this presentation and theinformation contained herein, (ii) to protect such information in the samemanner you protect your own confidential information, which shall be at least areasonable standard of care, and (iii) to not utilize any of the informationcontained herein except to assist with your evaluation of a potentialinvestment in the Company.

CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATIONTo the extent any forward-looking information in this presentation constitutes“future-oriented financial information” or “financial outlooks” within themeaning of applicable Canadian securities laws, such information is beingprovided to demonstrate the anticipated market penetration and the reader iscautioned that this information may not be appropriate for any other purposeand the reader should not place undue reliance on such future-orientedfinancial information and financial outlooks. Future-oriented financialinformation and financial outlooks, as with forward-looking information

generally, are, without limitation, based on the assumptions and subject to therisks set out below under the heading “Cautionary Note Regarding Forward-Looking Information”. Eve & Co Incorporated’s actual annual production, sales,distribution, financial position and results of operations may differ materiallyfrom management’s current expectations and, as a result, the Company’sannual production, income, expenses and net income may differ materiallyfrom the profiles provided in this presentation. Such information is presentedfor illustrative purposes only and may not be an indication of the Company’sactual annual production, financial position or results of operations.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This presentation includes forward-looking information and forward-lookingstatements within the meaning of Canadian securities laws. Statementscontaining the words “believe”, “expect”, “intend”, “should”, “seek”,“anticipate”, “will”, “positioned”, “project”, “risk”, “plan”, “may”, “estimate”or, in each case, their negative and words of similar meaning are intended toidentify forward-looking information. Forward-looking information involvesrisks and uncertainties including, but not limited to, the Company’s anticipatedbusiness strategies, anticipated trends in the Company’s business andanticipated market share, that could cause actual results or events to differmaterially from those expressed or implied by the forward-looking information,general business, economic and competitive uncertainties, regulatory risksincluding risks related to the expected timing of EVE’s licenses and expansions,market risks, risks inherent in manufacturing and agricultural operations as wellas other general risks of the cannabis industry. Such statements are based uponthe current beliefs and expectations of the Company’s management and aresubject to significant business, social, economic, political, regulatory,competitive and other risks, uncertainties, contingencies and other factors.Many assumptions are based on factors and events that are not within thecontrol of Eve & Co Incorporated. Actual future results may differ materiallyfrom historical results or current expectations.

These risks, uncertainties and assumptions could adversely affect the outcomeand financial effects of the plans and events described herein. In addition, even

if the outcome and financial effects of the plans and events described hereinare consistent with the forward-looking information contained in thispresentation, those results or developments may not be indicative of results ordevelopments in subsequent periods. Although Eve & Co Incorporated hasattempted to identify important risks and factors that could cause actualactions, events or results to differ materially from those described in forward-looking information, there may be other factors and risks that cause actions,events or results not to be as anticipated, estimated or intended. Forward-looking information contained in this presentation is based on the Company’scurrent estimates, expectations and projections, which the Company believesare reasonable as of the current date. The Company can give no assurance thatthese estimates, expectations and projections will prove to have been correct.You should not place undue reliance on forward-looking information, which isbased on the information available as of the date of this presentation. Forward-looking information contained in this presentation is as of the date of thispresentation and, except as required by applicable law, the Company assumesno obligation to update or revise them to reflect new events or circumstances.Historical statements should not be taken as a representation that such trendswill be replicated in the future. No statement in this presentation is intended tobe nor may be construed as a profit forecast. Additional information related toEVE, including risks and uncertainties, can be found on the Company’s SEDARprofile at www.sedar.com.

http://www.sedar.com/

Company Overview

o Eve & Co is located in Strathroy, Ontario and listed on the TSX-Venture Exchange (EVE) and the OTCQX (EEVVF)

o Natural MedCo Ltd., subsidiary of Eve & Co, holds a Standard Cultivation License and Standard Processing License and is authorized to sell plants, seeds, dried & fresh cannabis, cannabis oil, extracts, edibles & topicals

o Approval was granted for the 780,000 sq. ft. expansion in December 2019, increasing the combined capacity to approx. 1,000,000 sq. ft.

o On March 6, 2020, the Company received its European Union Certificate of Good Manufacturing Practice (EU GMP certificate) from the Government of Upper Bavaria, Germany

www.evecannabis.ca | TSX-V: EVE | OTCQX: EEVVF 3

PURPOSE BUILT FOR CANNABIS PRODUCTION

PRECISION ENVIRONMENTAL CONTROLS

BUILT TO EU SPECIFICATIONS

EU GMP CERTIFIED FACILITY

MASS SCALE ~ 50,000 KG/YEAR

Our Facility

HIGHLY AUTOMATED

Our Facility

After completion of our expansion strategy, our current facility has a combined capacity of 1,000,000 square feet. We completed Phase 2 construction in August 2019 having broken ground on the expansion in June 2018.

This new expansion was licensed by Health Canada in December 2019 as a grow area which enabled us to continue our production ramp-up to supply both the domestic and the global cannabis markets.

Anticipated annualized production of 50,000 kg of cannabis within the newly expanded facility.

www.evecannabis.ca | TSX-V: EVE | OTCQX: EEVVF 5

PHASE 1 EXPANSIONCURRENT FACILITY PHASE 2 EXPANSION

Operational Milestones


2018 2019 2020

JUNEConstruction commenced on Phase 2 expansion

JULYConstruction completed of additional flowering space

SEPTEMBERExtraction licence granted

DECEMBERApproval of second flowering room & packaging room

DECEMBERApproval to commence sales to provincially authorized retailers and distributors

AUGUST780,000 sq. ft. expansion completed

DECEMBERHealth Canada approval of expansion

JULYReceived licensing for sale of extracts, topicals and edibles

Q3 to Q4 2020Anticipated launch of suite of CPG Products

MARCHReceived EU GMP Certificate from the Government of Upper Bavaria, Germany

JUNESales licencegranted

PHASE 1 EXPANSIONCURRENT FACILITY PHASE 2 EXPANSION

Sales Channels and Strategies


RECREATIONAL MARKET (CANADA)o Sales will be made directly to

authorized distributors and retailers

o Approved for distribution in Newfoundland & Labrador, Manitoba and Saskatchewan and supply agreements with Ontario & B.C.

o Additionally offering white label solutions for other LPs and brands

MEDICINAL MARKET (CANADA)o Product to be sold directly to

other LPso Ongoing discussions for long-

term supply agreementso Commenced sales to medical

cannabis patients across Canada through our agreements with two medical cannabis online platforms (Major national grocery chain and Cannalogue).

MEDICINAL MARKET (EXPORT)o Entered into three supply

agreements with distributors for pharmaceutical and other products in Germany

Sales Strategy – Canadian Market


o Eve & Co balances brand awareness with pricing when selling cannabis in the Canadian recreational market

o Sales commenced to medical cannabis patients across Canada through agreements with two medical cannabis online platforms (Major national grocery chain and Cannalogue)

o Dried flower is currently offered in various sizes in addition to pre-rolled products

o Our fully automated packaging system maintains high quality control and reduces costs

SUPPLY AGREEMENTS

o We have entered into three non-exclusive agreements to supply cannabis to the European medical cannabis market. We are obtaining the requisite certification and licensing to fulfill our international supply obligations.

o We are building upon those agreements to access the EU cannabis market through established German operators.

o Development of additional sites within our strategic partnership in the EU for production and processing to address protectionism (Romania & Portugal).


Our Global Sales Strategy

Sales Strategy – International MarketEve & Co is continuing to build upon the three existing German supply agreements to access the EU cannabis market through established German operators.


Source:

https://mjbizdaily.com/global-cannabis-germany/https://investingnews.com/innspired/europe-medical-cannabis-cbd-cannabidiol/https://www.analyticalcannabis.com/articles/if-legalized-germanys-recreational-cannabis-market-could-be-worth-85-billion-by-2028-experts-312020

MARKET DATA

FUTURE MARKET

Estimated Medical Cannabis Patients in Germany by 2024 will

exceed 1 Million

Estimated Medical Cannabis Market

Value by 2028 will be €7.7 billion

Estimated Recreational Cannabis Market Worth

by 2028 will be €8.5 billion

Imports Serve an Estimated60,000

Medical Patients

Total flower Imports for Pharmacy

Dispensing in 2018

3,000 kg

Germany Population

80+million

SUPPLY AGREEMENTS

https://mjbizdaily.com/global-cannabis-germany/

https://investingnews.com/innspired/europe-medical-cannabis-cbd-cannabidiol/

https://www.analyticalcannabis.com/articles/if-legalized-germanys-recreational-cannabis-market-could-be-worth-85-billion-by-2028-experts-312020

Products

We currently cultivate a variety of strains and aim to offer various sizes and formats of our dried flower to the

market. We provide a quality choice at a competitive price.


Strategic Partnerships

In November 2019, Eve & Co entered into an LOI with Colio Estate Wines.

Eve & Co is working with Colio Estate Wines in the development and formulation of a cannabis-infused beverage.

Colio is the company behind the top-selling domestic flavoured wine beverage brand “Girls’ Night Out”. The picturesque winery is located in Harrow in the heart of the Essex / Pelee Island Coast Wine Country. Its wines are available at LCBO stores and any of the 14 Colio Wine Boutiques across the province.


In January 2020, Eve & Co entered into a LOI with ECS BioMed Inc. (“Dr. Kerklaan Therapeutics).

Eve & Co will be working with Dr. Kerklaan Therapeutics on developing a Natural CBD Relief Cream to bring to the Canadian recreational market. This topical pain cream, formulated by Dr. Kerklaan to ease discomfort, tension and stiffness.

Dr. Kerklaan Therapeutics hemp-based CBD products have been featured in Vogue, The Oprah Magazine, Forbes, Allure, Goop, Esquire and Rolling Stone magazines as well as other publications as a leading CBD skincare product.

Product Development


CURRENT CANNABIS 2.02020 Initiatives

Plants Edibles

Dried Flower Extracts

Pre-Rolls Topicals

We have been building strategic partnerships with established, trusted brands to further our consumer-packaged goods program in all product categories with anticipated launches scheduled for Q3 & Q4 2020.

Our Team


o We are comprised of a diverse team of professionals with experience in health, science, agriculture, cannabis, pharmaceuticals and regulated industries.

o Over 70% of Eve & Co’s management roles are held by women.

o At present, Eve & Co has a growing workforce of now over 100 employees which consists of 65% female employees.

Eve & Co Grow Team


Grow Team Greenhouse Experience

Agricultural Experience

Cannabis Experience

Education and Certifications Position

Melinda Rombouts 22 26 5 BSc. Honours Biology, Plant Biology, and BA, University of Waterloo

Former Grower, Grow team, consultation, QAP, SPIC

Dave Burch 15 41 10 University of Guelph Agricultural courses, Pesticide Handling Certification

Grower, Management

Tom Jobson 8 7 8 Agricultural Diploma, University of Guelph, Certified Crop Advisor, Licensed Exterminator

Lead Grower, IPM

Bindall Dabhi 1 6 1 BSc. Agriculture, Anand Agriculture University, India. Graduate Certificate, Environmental Management, Canadore College. Agricultural Business Management, Certificate, Fanshawe College.

Pest Specialist

Michelle Hoogstra 1 10 1 Agricultural Experience Assistant Grower

Mike Reaume 1 1 Pesticide Safety Course Assistant Grower

Andrew Stewart 7 5 2 BS Plant, Soil & Insect Science, University of Massachusetts: Amherst

Pest Team

David DiRisio 6 2 BSc. Earth Science, Brock University Chemical Application Specialist

Total Team Experience 61 95 30

Executive Team

RORY TAYLOR

Interim Chief Financial Officer

MELINDA ROMBOUTS

Chief Executive Officer and Director


IVAN ROSS VRÁNA

Vice President – Government Relations & Business Development

Prior to founding Natural MedCo, Ms. Rombouts was the president, manager and owner of numerous large-scale businesses in the agricultural, food, real estate and pharmaceutical industries and through these gained experience and knowledge in marketing, advertising, finance, project management and business development.

Ms. Rombouts has grown hundreds of varieties of plants and through this experience, she has gained extensive plant knowledge crucial to the growth of a healthy plant and high-quality product. She also has experience with Quality Assurance, GPP program and Standard Operating Procedures development, implementation and improvement with strict adherence to the regulations governing the pharmaceutical industry.

Ms. Rombouts holds a BA and BSc from the University of Waterloo with specialization in Plant Biology and Legal Studies.

Mr. Taylor joined the Eve & Co team in November of 2019 as financial controller and has been responsible for all aspects of financial management. Mr. Taylor has accumulated over 20 years of finance experience and prior to joining Eve & Co, he has held several CFO and senior financial roles in companies in the mining and metals, telecommunications and assurance practice sectors. He holds a Bachelor of Commerce degree from the University of Cape Town and is a South African qualified Chartered Accountant.

Ivan Ross is widely recognized as an industry expert in the field of cannabis for medical and recreational purposes. His experience in this sector dates back to his time with Health Canada when he helped develop the Government of Canada’s position regarding the use, production, distribution and regulation of cannabis for medical purposes. Since that time he has worked as a consultant with H+K Strategies (National Cannabis Practice) were he offered clients counsel and support in investor relations, communications, regulatory review, strategic partnerships, identification and outreach related to market opportunities in other countries and government affairs work at the federal, provincial and municipal levels. In the Spring of 2019, Ivan Ross joined Eve & Co. and is leading the company’s government relations and business development efforts.

Ivan Ross worked for the federal government for more than 18 years. He started his career at the Patented Medicine Prices Review Board as a policy analyst and went on to work at Health Canada where his work focused on pharmaceutical and cannabis policy at both the federal and provincial levels. During a two-year sabbatical, Ivan Ross worked for Innovative Medicines Canada as the director of government affairs, providing strategic insight and analysis. Since 2012, Ivan Ross has been working exclusively in the cannabis industry.

Ivan Ross is bilingual, a trained facilitator and holds a masters in public administration from Carleton University and a bachelor of arts (honours) in history from the University of Ottawa.

Board of Directors

YASIR NAQVIDirector

MELINDA ROMBOUTSCEO and Director


RAVI SOODDirector

Prior to founding Natural MedCo, Ms. Rombouts was the president, manager and owner of numerous large scale businesses in the agricultural, food, real estate and pharmaceutical industries and through these gained experience and knowledge in marketing, advertising, finance, project management and business development.

Ms. Rombouts holds a BA and BSc from the University of Waterloo with specialization in Plant Biology and Legal Studies.

She also has experience with Quality Assurance, GPP program and Standard Operating Procedures development, implementation and improvement with strict adherence to the regulations governing the pharmaceutical industry.

Mr. Sood is the managing director of Signal 8 Limited. Mr. Sood has been a founder of and the principal investor in several businesses in emerging markets and currently serves as Executive Chairman and Director of Galane Gold Ltd. (TSXV:GG) and Blockchain Power Trust (TSXV:BPWR) and as a director of Feronia Inc. (TSXV:FRN), and ICC Labs Inc. (TSXV:ICC).

He was the founder and Chief Executive Officer of Navina Asset Management Inc., a global asset management firm headquartered in Toronto, Canada. Mr. Sood led the investment activities of Navina and its predecessor company, Lawrence Asset Management Inc., from its founding in 2001 until he sold the firm in 2010.

Mr. Naqvi is the Chief Executive Officer of the Institute for Canadian Citizenship (ICC). Prior to joining the ICC, Mr. Naqvi served as a Member of Provincial Parliament for almost 11 years. In that time, he served as the Attorney General of Ontario,

Government House Leader, the Minister of Labour, and the Minister of Community Safety and Correctional Services. Mr. Naqvi was also a member of the Treasury Board and Management Board of Cabinet. Before being elected, Mr. Naqvi was the Associate Director and International Trade Counsel at the Centre for Trade Policy and Law, a non-profit think-tank affiliated with Carleton University and the University of Ottawa. He also practiced international trade, competition, regulatory and administrative law with major law firms in Ottawa. Mr. Naqvi has been cited as a “Community Builder” by United Way Ottawa and listed as one of the “Top 50 People in the Capital” by Ottawa Life magazine. In 2018, he was named on Canadian Lawyer’s “Top 25 Most Influential” list for advancing technological modernization in Ontario’s justice system. Most recently, Mr. Naqvi received the Lincoln Alexander Award by the Law Society of Ontario.

Capitalization Summary at March 31, 2020


SHAREHOLDER OWNERSHIP # OF SHARES % OF SHARES

Management and Insiders 85,173,940 29.6%

Widely Held 202,693,232 70.4%

Total 287,867,172

Warrants 37,565,000

Options 18,590,307

Total F/D 344,022,479

Cash $3.5 M

Production Process


Source Grow Flower Track & Trace

Harvest Drying Process/Packaging Distribution

Recent News


July 22, 2020 PharmaDrug Inc. Signs Cannabis Supply Agreement with Eve & Co

July 20, 2020 Eve & Co Receives Licence Amendment to Sell Cannabis Extracts, Edibles and Topicals

May 4, 2020 Eve & Co Announces Health Canada Approval of Additional Processing Area

April 2, 2020 Eve & Co Commences Canadian Medical Sales through Cannalogue

April 1, 2020 Eve & Co Announces Changes to its Board of Directors

March 6, 2020 Eve & Co Receives EU GMP Certification

January 30, 2020 Eve & Co Announces Exclusive LOI With Dr. Kerklaan Therapeutics

December 20, 2019 Eve & Co Completes First Shipment of Dried Flower Pre-Rolls to the Province of Ontario

December 16, 2019 Eve & Co Announces Health Canada Approval of 780,000 Square Foot Flowering Room

21

Eve is centered around

wellness,empowerment, and

education.

– three key elements that drive our business every day.

As a female-founded and female-led licensed holder, Eve isn’t just a

brand we own –

it’s who we are.

22www.evecannabis.ca | TSX-V: EVE | OTCQB: EEVVF

CONTACT

MELINDA ROMBOUTSCEO

+1 (855) NAT-MEDS+1 (855) 628-6337

[email protected]

CORPORATE PRESENTATION€¦ · presentation and, except as required by applicable law, the Company...

Documents

Transcript of CORPORATE PRESENTATION€¦ · presentation and, except as required by applicable law, the Company...